PharmaBoardroom

Global drug patent losses, 2012-2015

Each year, the leading innovative pharmaceutical companies around the world lose revenues when the patents on their innovative drugs expire, and…

The rise of generics in the Philippines

“The IMS Health figures show around three to four percent growth in the marketplace,” remarks Raymund Azurin, chief executive of Zuellig…

Portuguese generics: headroom for innovation?

In PharmaBoardroom’s first coverage of Portugal in 2007, generics represented 16 percent of the country’s pharmaceutical market, a tremendous feat…

Russian hospital market product ranking 2013 by sales value

This ranking for 2013 of the top 20 pharmaceutical products sold in the Russian hospital market during the year, organized by sales value, demoninates…

Top 20 Pharma Companies in Russia: Hospital Market 2013

As the rankings for the hospital market by sales value show, in Russia, it is multinational companies that dominate, with no local companies featuring…

Top 50 ranking of pharma companies in Poland, by sales, 2013

Although the Polpharma group takes first place in the 2013 rankings of pharmaceutical companies in Poland when measured by sales, it is the only…

Big Pharma Puts the UAE in its Sights

“Over the past twenty years, we have seen a drastic change in the socio-economic climate of the Gulf region and neighboring countries. There has…

Austerity leads to healthcare cuts in Portugal

When PharmaBoardroom came to Portugal in 2007, price cuts, payment delays and changes to the health system with each successive government…

Argentina: pharma sales by therapeutic area, 2012

Central nervous system, metabolic and cardiovascular products were the best performing therapeutic areas in Argentina in 2012, according to the graph…

Can the Philippines still make it as a manufacturing hub?

Before the introduction of universal healthcare (UHC), most major private hospitals in the Philippines had to rely on imported products. With the MNCs…

Canada: Quebec’s R&D expenditure

This graph shows Quebec's R&D expenditure as a percentage of GDP, in comparison to other provinces in Canada, as well as other OECD countries.

Taiwan: biotech industry revenues, 2004-2012

This graph shows the revenues from the biotech sector in Taiwan between 2004 and 2012, broken down to show applied biotech, pharmaceuticals and…

Tagged with